Chronic exposure of the blood-brain barrier to highly active antiretroviral therapy: Potential consequences on the CNS

Infectious Diseases in Clinical Practice

Volumn 12, Issue 3, 2004, Pages 158-162

  Langford, Dianne ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; INDINAVIR; NEVIRAPINE; NUCLEOSIDE ANALOG; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZALCITABINE; ZIDOVUDINE;

ARTICLE; BLOOD BRAIN BARRIER; BRAIN DISEASE; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROVASCULAR DISEASE; DRUG EXPOSURE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; LEUKOENCEPHALOPATHY; LONG TERM EXPOSURE; LYMPHOCYTE COUNT; MANIA; NEUROPATHOLOGY; PERIPHERAL NEUROPATHY; PSYCHOSIS; SYSTEMATIC REVIEW; VULNERABLE POPULATION;

EID: 2542444382     PISSN: 10569103     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.idc.0000129847.42132.4c     Document Type: Article

References (30)

1. McArthur JC, Haughey N, Gartner S, et al. Human immunodeficiency virus-associated dementia: an evolving disease. J Neurovirol. 2003;9:205-221.
2. Masliah E, DeTeresa R, Mallory M, et al. Changes in pathological findings at autopsy in AIDS cases for the last 15 years. AIDS. 2000;14:69-74.
3. Luciano CA, Pardo CA, McArthur JC. Recent developments in the HIV neuropathies. Curr Opin Neurol. 2003;16:403-409.
4. Kuritzkes DR, Currier J. Cardiovascular risk factors and antiretroviral therapy. N Engl J Med. 2003;348:679-680.
5. Powderly WG. Opportunities to improve clinical care in HIV disease: designing an effective antiretroviral drug regimen for your patient. Introduction. J Acquir Immune Defic Syndr. 2003;33(suppl 1):S5-S6.
6. Foster R, Olajide D, Everall IP. Antiretroviral therapy-induced psychosis: case report and brief review of the literature. HIV Med. 2003;4:139-144.
7. Clifford DB. AIDS dementia. Med Clin North Am. 2002;86:537-550. [vi]
8. Wendel KA, McArthur JC. Acute meningioencephalitis in chronic HIV infection: putative CNS escape. J Neurovirol. 2003;9:15-16.
9. Langford TD, Letendre SL, Marcotte TD, et al. Severe, demyelinating leukoencephalopathy in AIDS patients on antiretroviral therapy. AIDS. 2002;16:1019-1029.
10. Giner V, Fernandez C, Esteban MJ, et al. Reversible posterior leukoencephalopathy secondary to indinavir-induced hypertensive crisis: a case report. Am J Hypertens. 2002;15:465-467.
11. Neuenburg JK, Brodt HR, Herndier BG, et al. HIV-related neuropathology, 1985 to 1999: rising prevalence of HIV encephalopathy in the era of highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2002;31:171-177.
12. Langford T, Letendre SL, Larrea GJ. Changing patterns in the neuropathogenesis of HIV during the HAART era. Brain Pathol. 2002;11:306-312.
13. Gray F, Chretien F,Vallat-Decouvelaere AV, et al. The changing pattern of HIV neuropathology in the HAART era. J Neuropathol Exp Neurol. 2003;62:429-440.
14. Tozzi V, Uccella I, Larussa D, et al. Characteristics and factors associated with HIV-1 related neurocognitive disorders during HAART era. In: Khalili K, ed. 5th International Symposium of NeuroVirology, HIV Molecular and Clinical Neuroscience Workshop, Baltimore, MD, September 2-6, 2003. J Neurovirol. 2003;9(3):10.
15. Collazos J, Mayo J, Martinez E, et al. Contrast-enhancing progressive multifocal leukoencephalopathy as an immune reconstitution event in AIDS patients. AIDS. 1999;13:1426-1428.
16. Tagliati M, Simpson D, Morgello S, et al. Cerebellar degeneration associated with human immunodeficiency virus infection. Neurology. 1998;50:244-251.
17. Nath A. Human immunodeficiency virus (HIV) proteins in neuropathogenesis of HIV dementia. J Infect Dis. 2002;186(suppl 2):S193-S198.
18. Albright AV, Soldan SS, Gonzalez-Scarano F. Pathogenesis of human immunodeficiency virus-induced neurological disease. J Neurovirol. 2003;9:222-227.
19. Gartner S, Liu Y. Insights into the role of immune activation in HIV neuropathogenesis. J Neurovirol. 2002;8:69-75.
20. Masliah E, Ge N, Achim C, et al. Patterns of neurodegeneration in HIV encephalitis. NeuroAIDS. 1996;1:161-173.
21. Kakuda TN. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clin Ther. 2000;22:685-708.
22. Sutliff RL, Dikalov S, Weiss D, et al. Nucleoside reverse transcriptase inhibitors impair endothelium-dependent relaxation by increasing superoxide. Am J Physiol Heart Circ Physiol. 2002;283:H2363-H2370.
23. Irlbeck D, Stanhope MJ, Douady C, et al. Phylogenetic analyses of HIV-1 from an AIDS dementia patient suggest compartmentalized evolution in the mid-frontal gyrus of the brain. XI International Workshop on Drug Resistance and Treatment Strategies; 2002; Seville, Spain.
24. Maxwell S, Scheftner WA, Kessler HA, et al. Manic syndrome associated with zidovudine treatment. JAMA. 1988;259:3406-3407.
25. Peyriere H, Mauboussin JM, Rouanet I, et al. Management of sudden psychiatric disorders related to efavirenz. AIDS. 2001;15:1323-1324.
26. de la Garza L, Paoletti-Duarte S, Garcia-Martin C, et al. Efavirenz-induced psychosis. AIDS. 2001;15:1911-1912.
27. Sabato S, Wesselingh S, Fuller A, et al. Efavirenz-induced catatonia. AIDS. 2002;16:1841-1842.
28. Wise ME, Mistry K, Reid S. Drug points: Neuropsychiatric complications of nevirapine treatment. BMJ. April 13, 2002;324(7342):879.
29. Kandanearatchi A, Williams B, Everall IP. Assessing the efficacy of highly active antiretroviral therapy in the brain. Brain Pathol. 2003;13:104-110.
30. Yasuda H, Terada M, Maeda K, et al. Diabetic neuropathy and nerve regeneration. Prog Neurobiol. March 2003;69:(4);229-285.